Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2895 - A phase II study for triplet combination of oxaliplatin, irinotecan, and S-1 in patients with metastatic or recurrent gastric cancer


08 Oct 2016


Poster Display


Boram Han


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


B. Han1, S.R. Park2, H.S. Kim3, M. Ryu4, J. Kim5, S. Rho6, B.W. Kang7, K.H. Lee8, S.Y. Rha9, W.K. Kang10, Y. Kang4, D.Y. Zang3

Author affiliations

  • 1 Internal Medicine, Hallym University Medical Center Hallym University College of Medicine, 431-070 - Anyang/KR
  • 2 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul/KR
  • 3 Internal Medicine, Hallym University Medical Center Hallym University College of Medicine, Anyang/KR
  • 4 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
  • 5 Internal Medicine, Boramae Medical Center, Seoul/KR
  • 6 Internal Medicine, Seoul St. Mary's Hospital, of the Catholic University, Seoul/KR
  • 7 Oncology/hematology, Kyungpook National University Medical Center, 41404 - Daegu/KR
  • 8 Internal Medicine, Yeungnam University Medical Center, Daegu/KR
  • 9 Medical Oncology, Internal Medicine, Yonsei Severance Hospital Cancer Center, Seoul/KR
  • 10 Division Of Hematology-oncology, Department Of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/KR


Abstract 2895


Doublet chemotherapy of platinum and 5-fluorouracil is considered as a standard front-line treatment for patients with unresectable gastric cancer. Although addition of taxane or irinotecan to this regimen has yielded promising efficacy, it has been used in limited patients due to severe toxicities. To overcome this limitation, we evaluated the efficacy and safety of the combination of irinotecan, oxaliplatin, and S-1 for the treatment of unresectable gastric cancer.


Chemotherapy-naïve patients with pathologically proven unresectable recurrent or metastatic gastric adenocarcinoma were assessed for eligibility. Irinotecan at 135 mg/m2 and oxaliplatin at 65 mg/m2 were administered intravenously on day 1, and S-1 was administered orally at 80 mg/m2 on days 1–7 of every 14-day cycle, which have been derived from our phase I study.


Forty-three patients (median age 57 years) were enrolled. A total of 259 cycles of chemotherapy were administered (median of eight; range 1–23 cycles). Toxicities were evaluated in 41 patients, and the responses were evaluated in 32 patients. Major toxicities included grade 3/4 neutropenia (41.5%), febrile neutropenia (14.6%), abdominal pain (12.2%), and diarrhea (7.3%). The overall response rate was 59.4% [95% confidence interval (CI) 42.3-74.5%]. The median progression-free survival and overall survival were 8.4 months (95 % CI 5.5-11.3 months) and 13.1 months (95 % CI 11.8–14.5 months), respectively.


These data suggest that the oxaliplatin, irinotecan, and S-1 combination regimen is effective and relatively well tolerable, and it seems to have potential to be a reasonable therapeutic strategy in patients with unresectable gastric cancer.

Clinical trial identification

Legal entity responsible for the study

Hallym Sacred Heart Hospital Institutional Review Board


Korean Cancer Study Group


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings